文献速递主动脉疾病

Nellix 腔内动脉瘤封闭系统的单中心长期随访

A Single Centre Long Term Follow Up of the Nellix Endovascular Aneurysm Sealing System.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2023-11-10

该单中心前瞻性观察研究纳入2013年11月至2016年11月期间117例接受EVAS(Nellix系统)治疗的AAA患者,中位随访6.2年。结果显示Nellix失败率随时间升高,5年和7年免于Nellix失败率分别为54%和36%,免于开放手术转换率分别为63%和59%,结论强调EVAS后需 diligent 监测。

要点

  • 中位随访6.2年,5年和7年免于Nellix失败率分别为54%和36%。
  • 5年和7年免于开放手术转换率分别为63%和59%。
  • 动脉瘤相关死亡率为12%(14/117),二次囊腔破裂发生率为9.4%(11/117)。

核心结论

  • 长期随访显示Nellix失败率升高。
  • 作者认为EVAS治疗AAA后必须进行 diligent 监测,尤其当有前景的新器械进入临床使用时。

研究设计与样本

  • 观察性、前瞻性、单中心研究,纳入2013年11月至2016年11月期间接受EVAS(Nellix系统)初次AAA干预的患者117例。
  • 终点包括初次技术成功、Nellix器械失败、免于开放手术转换、免于二次干预、囊腔破裂、总死亡率和动脉瘤相关死亡率。

主要发现

  • 患者中位年龄75岁(IQR 70,81岁),男性占83%,中位AAA直径58 mm(IQR 54,60 mm),中位随访6.2年(IQR 5.6,6.8年)。
  • 初次技术成功率为100%,Nellix失败的中位时间为5.6年(IQR 3.3,7.4年)。
  • 5年和7年免于Nellix失败率分别为54%(95%CI 54.2-63.8%)和36%(95%CI 22.3-49.7%)。
  • 5年和7年免于开放手术转换率分别为63%(95%CI 53.2-72.8%)和59%(95%CI 47-71%)。
  • 二次干预率为11.4/100人年,5年和7年免于二次干预率分别为52%(95%CI 42.2-61.8%)和51%(95%CI 41.2-60.8%)。

临床怎么用

  • 作者认为EVAS治疗AAA后必须进行 diligent 监测,尤其当有前景的新器械进入临床使用时。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the clinical performance at long term follow up of endovascular aneurysm sealing (EVAS, Endologix Inc. Nellix, Irvine, CA, USA) in the treatment of abdominal aortic aneurysm (AAA). METHODS: Observational, prospective, single centre study of primary AAA interventions with EVAS (n = 117) from November 2013 to November 2016. Endpoints were primary technical success, Nellix device failure, freedom from open surgical conversion (OSC), freedom from secondary intervention, sac rupture, total mortality, and aneurysm related mortality at long term follow up. RESULTS: The median age was 75 years (interquartile range [IQR] 70, 81 years) and 83% were male. The median AAA diameter was 58 mm (IQR 54, 60 mm). The median length of follow up was 6.2 years (IQR 5.6, 6.8 years). Primary technical success was 100%. Median time to Nellix failure was 5.6 years (IQR 3.3, 7.4 years). Freedom from Nellix failure at five and seven years was 54% (95% confidence interval [CI] 54.2 - 63.8%) and 36% (95% CI 22.3 - 49.7%), respectively. Freedom from OSC at five and seven years was 63% (95% CI 53.2 - 72.8%) and 59% (95% CI 47 - 71%), respectively. The secondary intervention rate was 11.4/100 person years. Freedom from secondary intervention at five and seven years was 52% (95% CI 42.2 - 61.8%) and 51% (95% CI 41.2 - 60.8%), respectively. The cumulative mortality rate at five and seven years was 36% and 54%, respectively. Secondary sac rupture occurred in 9.4% (11/117) with a rate of 2/100 person years. Aneurysm related mortality was 12% (14/117) with a rate of 2.5/100 person years. The median survival was four years (IQR 3, 5.6 years). Thirty day mortality for acute OSC was 67% (n = 3) and 17.1% (6/35) for elective OSC. CONCLUSION: Long term follow up showed an increased failure rate. Diligent surveillance after endovascular AAA treatment is mandatory, especially when promising new devices are put into clinical use.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Mathisen SR, Berge ST. A Single Centre Long Term Follow Up of the Nellix Endovascular Aneurysm Sealing System. Eur J Vasc Endovasc Surg. 2023. PMID: 37951384. doi:10.1016/j.ejvs.2023.11.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。